Funds and ETFs ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-30 EDT 5-day change 1st Jan Change
8.7 USD +1.16% Intraday chart for ARS Pharmaceuticals, Inc. +2.35% +58.76%

ETFs positioned on ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.7 USD
Average target price
19 USD
Spread / Average Target
+118.39%
Consensus
  1. Stock Market
  2. Equities
  3. SPRY Stock
  4. Funds and ETFs ARS Pharmaceuticals, Inc.